EUVIMEDEUVIMED entdecken
Crossref

SPLUNC1 as a biomarker of pulmonary exacerbations in children with cystic fibrosis

E Ben-Meir, L Perrem, M Shaw, F Ratjen, H Grasemann

Journal of Cystic Fibrosis · 2024

DOI: 10.1016/j.jcf.2024.02.009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2024. Verfasst von E Ben-Meir und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Respiratory Medicine, Department of Paediatrics, The Hospital for Sick Children, Toronto, Canada; Translational Medicine, Research Instit…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Biomarkers, Sputum, Glycoproteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Short palate, lung, and nasal epithelium clone 1 (SPLUNC1) is an innate defence protein that acts as an anti-microbial agent and regulates airway surface liquid volume through inhibition of the epithelial sodium channel (ENaC). SPLUNC1 levels were found to be reduced in airway secretions of adults with cystic fibrosis (CF). The potential of SPLUNC1 as a biomarker in children with CF is unknown. METHODS: We quantified SPLUNC1, interleukin-8 (IL-8) and neutrophil elastase (NE) in sputum of CF children treated with either intravenous antibiotics or oral antibiotics for a pulmonary exacerbation (PEx)s, and in participants of a prospective cohort of CF children with preserved lung function on spirometry, followed over a period of two years. RESULTS: Sputum SPLUNC1 levels were significantly lower before compared to after intravenous and oral antibiotic therapy for PEx. In the longitudinal cohort, SPLUNC1 levels were found to be decreased at PEx visits compared to both previous and subsequent stable visits. Higher SPLUNC1 levels at stable visits were associated with longer PEx-free time (hazard ratio 0.85, p = 0.04). SPLUNC1 at PEx visits did not correlate with IL-8 or NE levels in sputum or forced expiratory volume in one second (FEV1) but did correlate with the lung clearance index (LCI) (r=-0.53, p < 0.001). CONCLUSION: SPLUNC1 demonstrates promising clinometric properties as a biomarker of PEx in children with CF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisBiomarkersSputumGlycoproteinsPhosphoproteinsInterleukin-8HumansMaleFemaleChildAnti-Bacterial AgentsProspective StudiesLeukocyte ElastaseAdolescentDisease ProgressionRespiratory Function Tests

Stichwörter der Autor:innen

BiomarkerChildrenCystic fibrosisPulmonary exacerbation

Substanzen

BiomarkersGlycoproteinsPhosphoproteinsInterleukin-8Anti-Bacterial AgentsLeukocyte ElastaseBPIFA1 protein, human

Autor:innen und Institutionen

  • Division of Respiratory Medicine, Department of Paediatrics, The Hospital for Sick Children, Toronto, Canada; Translational Medicine, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada; Univers…
  • Division of Respiratory Medicine, Department of Paediatrics, The Hospital for Sick Children, Toronto, Canada; Translational Medicine, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada.

Zitieren

APA

Ben-Meir, E., Perrem, L., Shaw, M., Ratjen, F., & Grasemann, H. (2024). SPLUNC1 as a biomarker of pulmonary exacerbations in children with cystic fibrosis. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2024.02.009

Vancouver

Ben-Meir E, Perrem L, Shaw M, Ratjen F, Grasemann H. SPLUNC1 as a biomarker of pulmonary exacerbations in children with cystic fibrosis. Journal of Cystic Fibrosis. 2024. doi:10.1016/j.jcf.2024.02.009

BibTeX
@article{BenMeir2024,
  author = {Ben-Meir, E and Perrem, L and Shaw, M and Ratjen, F and Grasemann, H},
  title = {SPLUNC1 as a biomarker of pulmonary exacerbations in children with cystic fibrosis},
  journal = {Journal of Cystic Fibrosis},
  year = {2024},
  doi = {10.1016/j.jcf.2024.02.009}
}
Kostenlos starten →